These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 33079077)

  • 1. Anti-PD-1 And Anti-PD-L1 Antibodies as Immunotherapy Against Cancer: A Structural Perspective.
    Córdova-Bahena L; Velasco-Velázquez MA
    Rev Invest Clin; 2020 Oct; 73(1):008-016. PubMed ID: 33079077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting regulatory T cells in anti-PD-1/PD-L1 cancer immunotherapy.
    Zhulai G; Oleinik E
    Scand J Immunol; 2022 Mar; 95(3):e13129. PubMed ID: 34936125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of natural products for anti-PD-1/PD-L1 immunotherapy against cancer.
    Ri MH; Ma J; Jin X
    J Ethnopharmacol; 2021 Dec; 281():114370. PubMed ID: 34214644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.
    Ohaegbulam KC; Assal A; Lazar-Molnar E; Yao Y; Zang X
    Trends Mol Med; 2015 Jan; 21(1):24-33. PubMed ID: 25440090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis.
    Gandini S; Massi D; Mandalà M
    Crit Rev Oncol Hematol; 2016 Apr; 100():88-98. PubMed ID: 26895815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature.
    Kopalli SR; Kang TB; Lee KH; Koppula S
    Recent Pat Anticancer Drug Discov; 2019; 14(2):100-112. PubMed ID: 30370857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.
    Jiang Y; Chen M; Nie H; Yuan Y
    Hum Vaccin Immunother; 2019; 15(5):1111-1122. PubMed ID: 30888929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microbiota-Regulated Outcomes of Human Cancer Immunotherapy via the PD-1/PD-L1 Axis.
    Patel J; Crawford JM
    Biochemistry; 2018 Feb; 57(6):901-903. PubMed ID: 29350031
    [No Abstract]   [Full Text] [Related]  

  • 10. Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy.
    Liu B; Song Y; Liu D
    J Hematol Oncol; 2017 Dec; 10(1):174. PubMed ID: 29195503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response.
    Luo M; Fu L
    Oncotarget; 2016 May; 7(20):29794-803. PubMed ID: 26919108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical applications of PD-L1 bioassays for cancer immunotherapy.
    Liu D; Wang S; Bindeman W
    J Hematol Oncol; 2017 May; 10(1):110. PubMed ID: 28514966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy.
    Wang Y; Ma R; Liu F; Lee SA; Zhang L
    Front Immunol; 2018; 9():374. PubMed ID: 29556232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment-Current Progress, Strategy, and Future Perspective.
    Guo L; Wei R; Lin Y; Kwok HF
    Front Immunol; 2020; 11():1508. PubMed ID: 32733486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.
    van Dam LS; de Zwart VM; Meyer-Wentrup FA
    Pediatr Blood Cancer; 2015 Feb; 62(2):190-197. PubMed ID: 25327979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment.
    Sato H; Okonogi N; Nakano T
    Int J Clin Oncol; 2020 May; 25(5):801-809. PubMed ID: 32246277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing cancer immunotherapy: Exploring strategies to target the PD-1/PD-L1 axis and analyzing the associated patent, regulatory, and clinical trial landscape.
    Kirthiga Devi SS; Singh S; Joga R; Patil SY; Meghana Devi V; Chetan Dushantrao S; Dwivedi F; Kumar G; Kumar Jindal D; Singh C; Dhamija I; Grover P; Kumar S
    Eur J Pharm Biopharm; 2024 Jul; 200():114323. PubMed ID: 38754524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.
    Sui H; Ma N; Wang Y; Li H; Liu X; Su Y; Yang J
    J Immunol Res; 2018; 2018():6984948. PubMed ID: 30159341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors.
    Del Re M; van Schaik RHN; Fogli S; Mathijssen RHJ; Cucchiara F; Capuano A; Scavone C; Jenster GW; Danesi R
    Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188463. PubMed ID: 33137405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives.
    Majidpoor J; Mortezaee K
    Clin Immunol; 2021 May; 226():108707. PubMed ID: 33662590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.